Implementation of Xpert MTB/RIF in 22 high tuberculosis burden countries: Are we making progress?

European Respiratory Journal

Volumn 50, Issue 2, 2017, Pages

  Cazabon, Danielle ^a   Suresh, Anita ^a   Oghor, Collins ^a   Qin, Zhi Zhen ^b   Kik, Sandra V ^c   Denkinger, Claudia M ^d   Pai, Madhukar ^a,e  

^a MCGILL UNIVERSITY   (Canada)

^b Stop TB Partnership   (Switzerland)

^c KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

^d The Global Alliance for Diagnostics   (Switzerland)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; DIAGNOSTIC TEST; DISEASE BURDEN; EXTRAPULMONARY TUBERCULOSIS; HEALTH CARE SYSTEM; HEALTH SURVEY; HUMAN; INFECTION RISK; LETTER; MICROSCOPY; ORGANIZATION; QUESTIONNAIRE; TREND STUDY; TUBERCULOSIS; WORLD HEALTH ORGANIZATION; BACTERIUM IDENTIFICATION; COST OF ILLNESS; INTERNATIONAL COOPERATION; ISOLATION AND PURIFICATION; MYCOBACTERIUM TUBERCULOSIS; SENSITIVITY AND SPECIFICITY;

BACTERIAL TYPING TECHNIQUES; COST OF ILLNESS; HUMANS; INTERNATIONALITY; MYCOBACTERIUM TUBERCULOSIS; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS;

EID: 85031502276     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00918-2017     Document Type: Letter

References (11)

1. World Health Organization. Status of Xpert MTB/RIF testing capacity and cartridge procurements as of December 2016. Geneva, WHO, 2017. www.who.int/tb/areas-of-work/laboratory/status_xpert_rollout_dec_2016.pdf?ua=1 Date last accessed: April 17, 2017.
2. Pai M, Furin J. Tuberculosis innovations mean little if they cannot save lives. eLife 2017; 6: e25956.
3. Qin ZZ, Pai M, Van Gemert W, et al. How is Xpert MTB/RIF being implemented in 22 high tuberculosis burden countries? Eur Respir J 2015; 45: 549-554.
4. Kik SV, Denkinger CM, Chedore P, et al. Replacing smear microscopy for the diagnosis of tuberculosis: what is the market potential? Eur Respir J 2014; 43: 1793-1796.
5. World Health Organization. Global Tuberculosis Report. Geneva, WHO, 2016. www.who.int/tb/publications/global_report/gtbr2016_executive_summary.pdf?ua=1 Date last accessed: April 17, 2017.
6. Mbonze NB, Tabala M, Wenzi LK, et al. Xpert® MTB/RIF for smear-negative presumptive TB: impact on case notification in DR Congo. Int J Tuberc Lung Dis 2016; 20: 240-246.
7. Charambira K, Ade S, Harries AD, et al. Diagnosis and treatment of TB patients with rifampicin resistance detected using Xpert(®) MTB/RIF in Zimbabwe. Public Health Action 2016; 6: 122-128.
8. Satyanarayana S, Nair SA, Chadha SS, et al. From where are tuberculosis patients accessing treatment in India? Results from a cross-sectional community based survey of 30 districts. PLoS One 2011; 6: e24160.
9. Revised National TB Programme. TB India 2017. Annual Status Report. New Dehli: Central TB Division, Directorate General of Health Services; 2017. http://tbcindia.nic.in/WriteReadData/TB%20India%202017.pdf Date last accessed: April 24, 2017.
10. Creswell J, Codlin AJ, Andre E, et al. Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries. BMC Infect Dis 2014; 14: 2.
11. World Health Organization Strategic and Technical Advisory Group for TB (STAG-TB). Use of high burden country lists for TB by WHO in the post-2015 era. Geneva, WHO, 2015. www.who.int/entity/tb/publications/global_report/high_tb_burdencountrylists2016-2020.pdf?ua=1 Date last accessed: April 17, 2017.